Skip to main content

First Patient Treated in the C-FLASH-01 ConformalFLASH® Clinical Trial

Written by Customer Service on . Posted in Public Companies.

First Patient Treated in the C-FLASH-01 ConformalFLASH® Clinical Trial

Louvain-la-Neuve, Belgium, October 21, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announced that the first patient has been treated in the C-FLASH-01 clinical trial (NCT07644585), the first human feasibility study investigating ConformalFLASH®1 proton therapy, at Penn Medicine under an Investigational Device Exemption (IDE) authorized by the U.S. Food and Drug Administration (FDA).

The study evaluates the feasibility of delivering fractionated ConformalFLASH® proton therapy using Bragg peak proton beams in patients requiring re-irradiation for head and neck cancer.

The first treatment marks an important milestone for FLASH radiotherapy and for IBA, as sponsor of this clinical trial. It reflects the company’s expanding role in generating clinical evidence for proton therapy innovation and bringing ConformalFLASH® closer from bench to bedside.

ConformalFLASH® is designed to combine the physical precision of proton therapy with ultra-high dose rate delivery capabilities to support clinical investigation of FLASH radiotherapy. By leveraging the Bragg peak and proprietary ConformalFLASH® technologies, the approach aims to deliver highly conformal treatments at ultra-high dose rates associated with FLASH delivery. The potential clinical benefits of this approach remain under investigation.

Olivier Legrain, Chief Executive Officer of IBA, commented: “For nearly forty years, IBA has helped pioneer particle accelerator technologies that have transformed cancer care. Today, we are reaching another important milestone. With C-FLASH-01, IBA is not only providing the technology enabling innovation, but also actively supporting its clinical evaluation through this sponsored clinical trial. This reflects our commitment to helping shape the future of proton therapy, working alongside leading clinical partners to bring promising innovations from the laboratory to clinical practice.”

This first treatment is supported by a strong ecosystem of specialized collaborators, each contributing key capabilities: RaySearch Laboratories provides a research version of its FLASH treatment planning system; 3D Systems supports the 3D printing of patient-specific devices, including the ConformalFLASH® Energy Modulator (CEM); .decimal supplies precision-milled patient-specific apertures; and IBA Dosimetry develops FLASH-enabled dosimetry solutions, including FLASH Lynx and MatriXX Air. The milestone demonstrates how complementary clinical, technological and treatment-planning expertise can help translate innovation from research into clinical evaluation.
For IBA, the evidence generated through C-FLASH-01 may help inform the future development of ConformalFLASH® technology and its potential integration into clinical proton therapy workflows.

***ENDS***

About C-FLASH-01
C-FLASH-01 (NCT07644585) is the first human feasibility study investigating fractionated ConformalFLASH® proton therapy delivered using Bragg peak proton beams. The study is being conducted at Penn Medicine under an FDA-authorized IDE and evaluates the feasibility of treating patients requiring re-irradiation for head and neck cancer who are not amenable to surgical resection.

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered as one of the most advanced forms of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,300 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

CONTACTS

Nathalie van Ypersele
Head of Communication and Sustainability
+32 10 475 890
communication@iba-group.com

Daniel Ernult
Corporate Communication Manager
+32 10 475 890
communication@iba-group.com

1 ConformalFLASH® is a registered brand of IBA’s Proton FLASH irradiation solution currently under research and development

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.